99% Purity Weight Loss Peptides Semaglutide Powder CAS 910463-68-2

• CAS No.: 910463-68-2
• Formula: C187h291n45o59
• EINECS: 203-405-2
• Type: Pharmaceutical Intermediates
• Appearance: White Powder
• Quality: Refined
• Model NO.: HRK-semaglutide
• Colour: White
• Product Name: Semaglutide
• Active Ingredient: Semaglutide
• Sample: Semaglutide Avaliable
• Einecs No: 203-405-2
• CAS No: 910463-68-2
• Mf: C187h291n45o59
• MW: 4113.57754
• Certificate: GMP ISO USP Bp
• Test: HPLC
• Grade Standard: Pharmaceutical Grade
• Type of Product: Cosmetic
• Assay: 99.9% Min
• Storage: Cool Dry Place
• Shelf Life: 2 Years Proper Storage
• Transport Package: 1kg Per Bag
• Specification: 99% min Semaglutide
• Trademark: Henrikang
• Origin: Shaanxi China
• Production Capacity: 5000kg/Year

Product Description

99% Purity Weight Loss Peptides semaglutide Powder CAS 910463-68-2

Product Name	99% Purity Weight Loss Peptides semaglutide Powder CAS 910463-68-2
CAS NO	910463-68-2
Appearance	White Powder
Molecular Formula	C187H291N45O59
Storage	Keep in a cool, dry, dark location
Shelf Life	24 months when properly stored

Sommarutide is a long-acting formulation based on the basic structure of Liraglutide, which is more effective in the treatment of type 2 diabetes. Sommarutide was prepared by solid-liquid synthesis method. Linear peptide Aib8, Arg34GLP-1(7-37) and aliphatic acylating agent were prepared by solid-phase synthesis. Under alkaline conditions, the synthetic aliphatic acylating agent was used to modify the linear peptide Lys26 to obtain sommaruteptide. The biological activity of the self-made samples was determined by time-resolved fluorescence resonance energy transfer immunoassay.

semaglutide is a long-acting formulation based on the basic structure of Liraglutide, which is more effective in the treatment of type 2 diabetes. Novo Nordisk has completed six PhaseIIIa studies for its Sommarutide injection and has submitted a New drug registration application for its weekly injection to the US Food and Drug Administration (FDA) and a marketing authorization application (MAA) to the European Medicines Agency (EMA) on 5 December 2016. A once-daily oral formulation of Sommarutide, on the other hand, is currently in phase III.